(Puur Pulles Photography) Dr Mette Hazenberg is a Professor in Hematology and Cell Therapy at Amsterdam University Medical Center and Sanquin Research, Amsterdam. Her work as a clinical haematologist and principal investigator is focused on the immunology of allogeneic hematopoietic stem cell transplantation (HCT). Taking advantage of the strong immune responses allogeneic HCT recipients can
Biography
(Puur Pulles Photography)
Dr Mette Hazenberg is a Professor in Hematology and Cell Therapy at Amsterdam University
Medical Center and Sanquin Research, Amsterdam. Her work as a clinical haematologist and
principal investigator is focused on the immunology of allogeneic hematopoietic stem cell
transplantation (HCT). Taking advantage of the strong immune responses allogeneic HCT
recipients can generate against their malignancies, she identified acute myeloid leukemia
(AML) specific antibodies that have great potential as therapeutic antibodies. Donor immune
cells can however turn against healthy tissues of the stem cell recipient, resulting in – often
devastating – graft versus host disease (GvHD). Hazenberg is working towards a better
understanding of the immunological processes underlying the emergence and clinical
behaviour of GvHD. Damage to tissues and the microbiome play an important role in GVHD
pathophysiology and research in the Hazenberg group is focused on the tissue protective
roles of innate lymphoid cells (ILC) and the microbiome and employment thereof to prevent
and treat GvHD. She has been awarded several prestigious grants, including a Netherlands
Organisation for Scientific Research (NWO) Clinical Fellowship, a Landsteiner (LSBR)
Fellowship and NWO Talent Scheme VIDI and Aspasia grants. She is among others member of
the National Institute for Public Health (RIVM) working group on COVID-19 vaccination in
immunocompromised patients.
All session by Mette D. Hazenberg
11:30
